Esophageal Cancer Clinical Trials

CLINICAL TRIAL 21589
BASECAMP-1: An Observational Study Obtaining Solid Tumor Tissue from Subjects with Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing
Condition: Immunotherapy
Intervention:

CLINICAL TRIAL 21664
Phase 1b/3 z=Global, Randomized, Controlled, Open-Label Trial Comparing Treatment with RYZ101 to Standard of Care (SoC) Therapy in Subjects with Inoperable, Advanced, Somatostatin Receptor Expressing (SSTR+), Well-Differentiated Gastro-Enteropancreatic Neuroendocrine Tumors (GEP-NETs) that have Progressed Following Prior 177Lulabelled Somatostatin Analogue (177Lu-SSA) Therapy (ACTION-1).
Condition: Gastrointestinal Tumor
Intervention: Amino acids (); Granisetron (); Lanreotide (); Ondansetron (); RYZ101 (); Sunitinib (); Zofran (Ondansetron); everolimus (RAD001); octreotide LAR ()

CLINICAL TRIAL 22685
Phase 1/1B, Multicenter, Open-Label, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors
Condition: Multiple
Intervention: RMC-6236 (Daraxonrasib); RMC-9805 (Zoldonrasib)

CLINICAL TRIAL 23121
Exercise Prehabilitation for Locoregional Esophageal Cancer: A Pilot Study
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 23230
Support through remote observation and nutrition guidance program for individuals with gastroesophageal cancer (STRONG-GEC)
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 23549
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); VET3-TGI ()

CLINICAL TRIAL 23660
A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants with Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention:

CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()

CLINICAL TRIAL 23716
AVENTINE-1: A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-1418 as a single agent and in combination therapy in patients with locally advanced or metastatic solid tumors
Condition: Multiple
Intervention: AVZO-1418 (); AZD9291 (Osimertinib); Osimertinib (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 23766
A First-in-Human Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FID-022 as Monotherapy in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: FID-022 ()

CLINICAL TRIAL 23787
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
Condition: Multiple
Intervention: ALX2004 ()

CLINICAL TRIAL 23829
A Phase 1/2 First-in-Human, Open-Label, Dose Escalation and Expansion Trial of TAK-505 Monotherapy in Participants with Unresectable Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: TAK-505 ()

CLINICAL TRIAL 23965
A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single agent and in Combination with pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: BH3120 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 24028
OMNIRAY, A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults with GRPR-Positive Advanced Solid Tumors
Condition: Multiple
Intervention: Abemaciclib (); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Imlunestrant (); LY2835219 (Abemaciclib); LY4257496 (); LY4257529 (); Letrozole (); Xeloda (capecitabine); capecitabine (); fulvestrant ()

CLINICAL TRIAL 24071
Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients with Advanced KRAS G12V-Mutant Solid Tumors
Condition: Multiple
Intervention: Cetuximab (); Daraxonrasib (); Erbitux (Cetuximab); RMC-5127 (); RMC-6236 (Daraxonrasib)

CLINICAL TRIAL 24072
A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [18F] FAPI-74 PET/CT for the Detection of Metastatic Disease in Adults with Gastric or Esophageal Cancer (FAPI-GO)
Condition: Gastrointestinal Tumor
Intervention: [18F] FAPI-74 ()

CLINICAL TRIAL 24095
Phase 1/2a Open-Label Clinical Trial Evaluating VBC101, an EGFR and cMET Targeted Bi-Specific Antibody Drug Conjugate, in Participants With Advanced Solid Tumor Malignancies
Condition: Multiple
Intervention: VBC101 ()

CLINICAL TRIAL 24103
A First-in-Human Phase 1 Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation
Condition: Multiple
Intervention: KST-6051 ()

CLINICAL TRIAL 24190
A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)
Condition: Multiple
Intervention: LY4337713 (); [18F] FAPI-74 (); [Ga-68]-FAPI-46 ()

CLINICAL TRIAL 24236
A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: 5-fluorouracil (); Alimta (Pemetrexed); ERAS-0015 (); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Oxaliplatin (); Panitumumab (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxotere (docetaxel); Vectibix (Panitumumab); carboplatin (); cisplatin (); docetaxel (); eloxatin (Oxaliplatin); gemcitabine (); leucovorin ()

CLINICAL TRIAL 24244
A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); BMS-936558 (Nivolumab); Nivolumab (Opdivo); Oxaliplatin (); Pumitamig (); Xeloda (capecitabine); capecitabine (); eloxatin (Oxaliplatin); leucovorin ()

CLINICAL TRIAL 24258
A Phase 1 Study to Evaluate the Safety and Efficacy of DISP-10 in Participants with Advanced Gastrointestinal Cancers
Condition: Immunotherapy
Intervention: Cyclophosphamide (); DV-10 (); Fludarabine (); Idecabtagene Vicleucel ()

CLINICAL TRIAL 24291
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Enrichment, and Dose-Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BLU-924 (SAR449336) as Monotherapy and Combination Therapy in Participants with Advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Harboring KRAS Mutations
Condition: Multiple
Intervention: BLU-924 ()

CLINICAL TRIAL 24299
A study of a mutant-selective inhibitor, CGT6297, in patients with advanced solid tumors harboring PIK3CA mutations
Condition: Multiple
Intervention: CGT6297 ()

CLINICAL TRIAL 24394
A Multi-center, Open-label, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AN9025 in Participants with Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Condition: Multiple
Intervention: AN9025 ()